The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron Pharmaceuticals’ drug Dupixent for use in treating chronic spontaneous urticaria (CSU), a skin disorder caused by an overreactive immune response. This approval signals a new method of treating CSU for patients aged 12 and up who haven’t responded to antihistamines. Dupixent’s approval was based on successful phase 3 trials.
Marks & Spencer online disruption a 'bruise' to reputation, analyst says – BBC
Marks & Spencer’s online disruptions have negatively impacted its reputation, according to an analyst. The issues faced during peak demand periods have been described as
